From the molecular language of life, into medicine.

We’re developing PDRN medicines from short, defined DNA fragments—produced without animal-derived sources and engineered for consistent length and purity.

About Synthena
A hand lifts one small vial of pale liquid from a row of vials standing on a light box in a dark laboratory
PDRN platform

Rethinking how PDRN is made.

Most PDRN used today is extracted from animal tissue and contains DNA fragments of varying lengths. Our platform takes a different approach, producing PDRN from plant- and microbe-based sources, with a defined fragment length and a process designed for pharmaceutical-grade consistency and purity.

Explore our platform
Pipeline

Advancing PDRN across five areas of human biology

We’re developing PDRN-based medicines across the skin, joints, circulation, gut and nervous system, starting with the skin.

View our pipeline
DermatologyPreclinical
MusculoskeletalResearch
CardiovascularResearch
DigestiveResearch
NervousResearch
Synthena in numbers
389published studies on PDRN in the scientific literature
5areas of human biology under investigation
1university research partner: Nguyen Tat Thanh University
2025founded in Hong Kong, with research in Vietnam
Marshon Nguyen, founder of Synthena, seated at a meeting table at Nguyen Tat Thanh University
Company

Built around verification

Our team is intentionally small: a founder, researchers in Vietnam and a university laboratory, united by one discipline: questioning, testing and verifying the work at every step.

Meet the company
Latest news

Bring good science further

We believe meaningful medicines are rarely built alone.

If you’re part of a university, research institute or technology team working on science that could move PDRN medicine forward, we’d like to hear from you.

Contact us